Kell Østerlind
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 75
- Lung Cancer Research Studies 52
- Peptidase Inhibition and Analysis 16
- Pancreatic and Hepatic Oncology Research 11
- Epidemiology 39
- Neuroendocrine Tumor Research Advances 38
- Co-authors
- Heine H. Hansen (21 shared papers)P Dombernowsky (26 shared papers)Jørgen Gliemann (3 shared papers)J. Vinten (2 shared papers)Fred R. Hirsch (13 shared papers)Per Kragh Andersen (3 shared papers)M Hansen (9 shared papers)Daniel C. Ihde (3 shared papers)
- Journals
- Lung Cancer (15 papers)Journal of Clinical Oncology (10 papers)British Journal of Cancer (9 papers)Annals of Oncology (8 papers)Acta Oncologica (3 papers)
- Partner nations
- DenmarkUnited KingdomUnited States
In The Last Decade
Kell Østerlind
103 papers receiving 5.8k citations
Kell Østerlind's Hit Papers
Peers
Comparison fields: 5 of 128
- Oncology 3.5k
- Pulmonary and Respiratory Medicine 2.1k
- Epidemiology 1.4k
- Cancer Research 594
- Hepatology 132
Countries citing papers authored by Kell Østerlind
This map shows the geographic impact of Kell Østerlind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kell Østerlind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kell Østerlind more than expected).
Fields of papers citing papers by Kell Østerlind
This network shows the impact of papers produced by Kell Østerlind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kell Østerlind. The network helps show where Kell Østerlind may publish in the future.
Co-authors
The 25 scholars most cited alongside Kell Østerlind, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 108 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Hit paper breakdown → | 2008 | 1027 |
| 2 | A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer Hit paper breakdown → | 1992 | 991 |
| 3 | 1972 | 343 | |
| 4 | Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. | 1994 | 271 |
| 5 | 1995 | 223 | |
| 6 | 1989 | 212 | |
| 7 | 1987 | 188 | |
| 8 | 1976 | 132 | |
| 9 | 1986 | 105 | |
| 10 | 2016 | 104 | |
| 11 | 1983 | 94 | |
| 12 | 1987 | 87 | |
| 13 | 1996 | 82 | |
| 14 | 2013 | 76 | |
| 15 | Staging and prognostic factors in small cell carcinoma of the lung. | 1983 | 76 |
| 16 | 1986 | 75 | |
| 17 | 2011 | 75 | |
| 18 | 1985 | 70 | |
| 19 | 2016 | 70 | |
| 20 | 1986 | 70 |
About Kell Østerlind
Kell Østerlind is a scholar working on Oncology, Epidemiology, Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research, having authored 108 papers that have together received 6.1k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (52 papers), Neuroendocrine Tumor Research Advances (38 papers), Lung Cancer Treatments and Mutations (19 papers), Peptidase Inhibition and Analysis (16 papers), Cancer therapeutics and mechanisms (12 papers), Pancreatic and Hepatic Oncology Research (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Neuroblastoma Research and Treatments (5 papers). The work is most often cited by research in Oncology (3.5k citations), Pulmonary and Respiratory Medicine (2.1k citations), Epidemiology (1.4k citations), Cancer Research (594 citations) and Hepatology (132 citations). Kell Østerlind has collaborated with scholars based in Denmark, United Kingdom and United States. Frequent co-authors include Heine H. Hansen, P Dombernowsky, Jørgen Gliemann, J. Vinten, Fred R. Hirsch, Per Kragh Andersen, M Hansen, Daniel C. Ihde, Steen Gammeltoft and David H. Johnson. Their work appears in journals such as Lung Cancer, Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology and Acta Oncologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.